ATOS
What one share of Atossa Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and other breast conditions. Our lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/ selective estrogen receptor degrader (SERM/D) currently in Phase 2 clinical development.
Atossa Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.34 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$4.12 |
| Cash and investments | $2.61 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$32.41 | — | −$27.35 | — | $12.27 |
| 2017 | — | −$164.51 | — | −$101.47 | — | — |
| 2018 | — | −$82.56 | $0.40 | −$32.73 | — | $22.59 |
| 2019 | — | −$30.43 | $0.01 | −$16.13 | — | $21.61 |
| 2022 | — | −$3.19 | $0.00 | −$2.46 | — | $13.97 |
| 2023 | — | −$3.58 | $0.00 | −$2.49 | — | $10.90 |
| 2024 | — | −$3.04 | $0.00 | −$2.51 | — | $8.30 |
| 2025 | — | −$4.04 | $0.00 | −$3.46 | — | $4.57 |